San Francisco, June 21st, 2017 – Recardio Inc. today announced that it has appointed its newly formed Scientific Advisory Board, reflecting the company’s entering the clinical phase 2 development in 2017.
This newly formed Scientific Advisory Board represents a selection of clinicians, who already contributed to the past clinical development and are from 2017 supporting Recardio in the scientific and clinical development of its regenerative therapy for acute myocardial infarction.
The Chairman of the Advisory is Richard A Schatz, MD, Interventional Cardiology, Research Director Scripps Clinic, Director of Gene and Stem Cell Research, Professor of Medicine, La Jolla, USA.
Further board members include:
Bernd Jilma, MD, Professor of Clinical Pharmacology and Internal Medicine, Vice Chair Department of Clinical Pharmacology, Medical University of Vienna, Austria
Götz Münch, MD, Professor of Medicine, Cardiologist and Internal Medicine Specialist, Munich, Germany
Keith G. Oldroyd, MD, Interventional Cardiologist, West of Scotland Regional Heart & Lung Centre, Golden Jubilee National Hospital, Glasgow, UK
Thomas J. Povsic, MD, Ph.D. Associate Professor of Medicine, Head of Advanced Biomarkers Research, Duke Clinical Research Institute, Durham, USA
Dr. Roman Schenk, RECARDIO Executive Chairman commented: “We are extremely proud that key opinion leaders like Richard, Bernd, Götz, Keith and Tom have joined our Advisory Board and will contribute with their excellent and long lasting scientific and clinical experience to our development program in the cardiovascular area.”
Recardio Inc. is a clinical-stage life science company focusing on regenerative therapies for cardiovascular diseases. The company’s lead drug candidate, Dutogliptin, is a DPP-IV inhibitor that has demonstrated significant effects in activating SDF-1, a protein that is critical for cardiac regeneration. The company is initiating a Phase 1/2 clinical program, seeking to fully develop the therapeutic platform as a regenerative medication for patients with various cardiovascular diseases including acute myocardial infarction and chronic heart failure, with the potential of improving heart function, quality of life and survival. For more information, visit: https://recardio.eu/